Origin of debate of using Avastin vs. Lucentis

- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Avastin vs. Lucentis: The Origin of the Debate

Posted By Irv Arons On April 29, 2011 @ 11:17 am In Consultant Articles,Industry News,Macular Degeneration,New Technologies,Research,Retina | Comments Disabled

Earlier today we published a post on the outcome of the CATT Study testing the effectiveness of Lucentis vs. Avastin ^[1].

The interesting historical question is how did this debate arise in the first place? I have written in my online Journal about the splash Dr. Philip Rosenfeld made at the 2005 American Society of Retinal Specialists (ASRS) Meeting, when he presented on his first patients treated with a $50 off-label dose of Avastin and advised he was getting the same results as with (when approved) $2000 per dose Lucentis.

I also wrote about how Wendy Bedale described the invention of Avastin and Lucentis by Genentech.

Now, here is the rest of the story of how Dr. Rosenfeld came up with the idea of using Avastin in the first place, as told in November 2006 by (then) Miami Herald reporter Jacob Goldstein – Avastin/Lucentis Update 46: Avastin – The Rest of the Story ^[2].

Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/005288-avastin-vs-lucentis-the-origin-of-the-debate/

URLs in this post:

[1] CATT Study testing the effectiveness of Lucentis vs. Avastin: http://eyedocnews.com/005323-catt-study-finds-no-difference-between-avastin-and-lucentis-in-stopping-progression-of-wet-macular-degeneration/

[2] Avastin/Lucentis Update 46: Avastin – The Rest of the Story: http://tinyurl.com/Avastin46

Click here to print.